Drug interactions
Efgartigimod alfa + Obinutuzumab
Severity: Moderate
Efgartigimod alfa and Obinutuzumab: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Efgartigimod blocks the neonatal Fc receptor, which normally recycles IgG antibodies, and this may lower circulating levels of IgG-based drugs such as obinutuzumab. Reduced exposure could weaken its antitumor or B-cell depleting effect.
What this interaction means in plain words
Efgartigimod alfa and Obinutuzumab can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Efgartigimod alfa belongs to Miscellaneous; Obinutuzumab belongs to Oncology.
Why it happens
Efgartigimod competitively blocks FcRn, increasing catabolism of IgG monoclonal antibodies and lowering their exposure.
What to do
Monitor for reduced response to obinutuzumab, such as B-cell counts or disease control. Consider timing the antibody dose away from efgartigimod, or alternatives if long-term combined use is required.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Efgartigimod alfa and Obinutuzumab, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Obinutuzumab
Other interactions of Efgartigimod alfa
- Adalimumab + Efgartigimod alfa Moderate
- Ado-trastuzumab + Efgartigimod alfa Moderate
- Basiliximab + Efgartigimod alfa Moderate
- Bevacizumab + Efgartigimod alfa Moderate
- Brentuximab + Efgartigimod alfa Moderate
- Denosumab + Efgartigimod alfa Moderate
Frequently asked questions
Can I take Efgartigimod alfa with Obinutuzumab?
MediHelp rates the interaction as moderate. Efgartigimod alfa and Obinutuzumab can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Efgartigimod blocks the neonatal Fc receptor, which normally recycles IgG antibodies, and this may lower circulating levels of IgG-based drugs such as obinutuzumab. Reduced exposure could weaken its antitumor or B-cell depleting effect.
How serious is the interaction between Efgartigimod alfa and Obinutuzumab?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor for reduced response to obinutuzumab, such as B-cell counts or disease control. Consider timing the antibody dose away from efgartigimod, or alternatives if long-term combined use is required.
What other medicines interact with Obinutuzumab?
MediHelp also lists interactions of Obinutuzumab with, for example, Measles mumps and rubella vaccine, Adenovirus types 4 and 7 live, Axicabtagene ciloleucel. The full list is on the Obinutuzumab page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
